Astellas Pharma’s Post

Although direct comparisons are always preferred, it is not always possible or affordable to conduct them. Experts can utilize other methods, including a matching-adjusted indirect comparison (MAIC). With this method, research can be conducted to understand and compare treatment outcomes – even when the clinical studies in question have population differences. Professor Andrew Armstrong, Director of Research at Duke Cancer Institute, explores what MAIC analyses entail, including their benefits and limitations, and how variations in patient characteristics can be adjusted, to give a comparative data picture.   #MAICanalysis #ScienceFirstForPatients

Mohamed Elshahawi, MD

Enterprise Leader | Global Marketing Executive & Senior Medical Affairs leader | Oncology & Prostate cancer disease| Geographical expertise GCC, MEA, Russia, Turkey, APAC, LATAM, Europe, China and Japan

1w

Great post, Andrew Armstrong MAIC is such a valuable approach in today’s complex research landscape—especially when head-to-head trials aren’t feasible “we see this a lot in PCa”. It’s fascinating how this method helps bridge evidence gaps by adjusting for the differences in population, ultimately supporting better-informed treatment decisions. Thanks for highlighting both the potential and the limitations so clearly—science-driven innovation like this truly puts patients first. #MAICanalysis #ScienceFirstForPatients

Like
Reply
Brandon Casamassima

US Oncology/Ophthalmology Regional Account Director

2w

Great insight Andrew Armstrong! Hope you are well and looking forward to seeing you at the upcoming Duke events!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics